Pyrotinib varied from the second-line drug for the treatment of advanced HER-2 positive breast cancer to the first-line treatment (Xu et al., 2022). Regorafenib approved for second-line therapy but used as a first-line agent alone for advanced hepatocellular carcinoma (Bai et al., 2023). This evidence concerns the gene ERBB2 and breast cancer.